Laura Kranaster

List of Publications by Year
in descending order

42 papers	1,077 citations	430442 18 h-index	433756 31 g-index
43 all docs	43 docs citations	43 times ranked	1333 citing authors

#	Article	IF	Citations
1	Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 255-261.	1.8	104
2	Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 575-582.	1.8	100
3	Decreased utilization of mental health emergency service during the COVID-19 pandemic. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 377-379.	1.8	99
4	Electroconvulsive therapy increases temporal gray matter volume and cortical thickness. European Neuropsychopharmacology, 2016, 26, 506-517.	0.3	84
5	Bispectral Index Monitoring and Seizure Quality Optimization in Electroconvulsive Therapy. Pharmacopsychiatry, 2013, 46, 147-150.	1.7	61
6	Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 227-232.	1.8	57
7	Electroconvulsive therapy induced gray matter increase is not necessarily correlated with clinical data in depressed patients. Brain Stimulation, 2019, 12, 335-343.	0.7	49
8	New Evidence for Seizure Quality Improvement by Hyperoxia and Mild Hypocapnia. Journal of ECT, 2014, 30, 287-291.	0.3	43
9	Antidepressant efficacy of electroconvulsive therapy is associated with a reduction of the innate cellular immune activity in the cerebrospinal fluid in patients with depression. World Journal of Biological Psychiatry, 2018, 19, 379-389.	1.3	33
10	Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 781-786.	1.8	31
11	The â€œForgottenâ€•Treatment of Alcohol Withdrawal Delirium With Electroconvulsive Therapy: Successful Use in a Very Prolonged and Severe Case. Clinical Neuropharmacology, 2017, 40, 183-184.	0.2	30
12	A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 819-830.	1.8	23
13	Ultra-High-Frequency Left Prefrontal Transcranial Magnetic Stimulation as Augmentation in Severely Ill Patients with Depression: A Naturalistic Sham-Controlled, Double-Blind, Randomized Trial. Neuropsychobiology, 2012, 66, 141-148.	0.9	22
14	Cytokine-mediated cellular immune activation in electroconvulsive therapy: A CSF study in patients with treatment-resistant depression. World Journal of Biological Psychiatry, 2020, 21, 139-147.	1.3	22
15	Serum lipid profile changes after successful treatment with electroconvulsive therapy in major depression: A prospective pilot trial. Journal of Affective Disorders, 2016, 189, 85-88.	2.0	21
16	Electroconvulsive therapy enhances the anti-ageing hormone Klotho in the cerebrospinal fluid of geriatric patients with major depression. European Neuropsychopharmacology, 2018, 28, 428-435.	0.3	21
17	Electroconvulsive therapy selectively enhances amyloid Î² 1â€“42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology, 2016, 26, 1877-1884.	0.3	20
18	Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. Neuropsychobiology, 2019, 77, 13-22.	0.9	20

#	Article	IF	Citations
19	Cerebrospinal fluid diagnostics in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 529-530.	1.8	18
20	Protein S-100 and neuron-specific enolase serum levels remain unaffected by electroconvulsive therapy in patients with depression. Journal of Neural Transmission, 2014, 121, 1411-1415.	1.4	18
21	Evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 35-45.	1.1	18
22	Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapyâ€"A pilot study. Journal of Affective Disorders, 2019, 253, 449-453.	2.0	17
23	A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 859-865.	1.8	16
24	Impact of psychiatric comorbidity on the severity, short-term functional outcome, and psychiatric complications after acute stroke . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1823-1831.	1.0	15
25	Burst Suppression. Journal of ECT, 2013, 29, 25-28.	0.3	13
26	The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 911-919.	1.8	12
27	Methylome-wide change associated with response to electroconvulsive therapy in depressed patients. Translational Psychiatry, 2021, 11, 347.	2.4	12
28	Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1389-1394.	1.0	11
29	Preliminary evaluation of clinical outcome and safety of ketamine as an anesthetic for electroconvulsive therapy in schizophrenia. World Journal of Biological Psychiatry, 2014, 15, 242-250.	1.3	10
30	Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 457-463.	1.8	9
31	Brain-Derived Neurotrophic Factor in the Cerebrospinal Fluid Increases During Electroconvulsive Therapy in Patients With Depression. Journal of ECT, 2020, 36, 193-197.	0.3	8
32	Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response. Journal of ECT, 2017, 33, 117-121.	0.3	7
33	Peripheral levels of the anti-aging hormone Klotho in patients with depression. Journal of Neural Transmission, 2019, 126, 771-776.	1.4	7
34	Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: a preliminary study. Journal of Neural Transmission, 2013, 120, 1733-1736.	1.4	6
35	Association between the novel seizure quality index for the outcome prediction in electroconvulsive therapy and brain-derived neurotrophic factor serum levels. Neuroscience Letters, 2019, 704, 164-168.	1.0	6
36	Rethinking Restimulation. Journal of ECT, 2012, 28, 248-249.	0.3	4

#	Article	IF	Citations
37	ECT seizure quality and serum BDNF, revisited. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 359-360.	1.8	4
38	Electroconvulsive Therapy in a Patient With Ultrarapid Cycling Bipolar Disorder:A Case Report. Journal of ECT, 2017, 33, e40-e41.	0.3	3
39	Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. Journal of Neural Transmission, 2017, 124, 1641-1645.	1.4	3
40	A New Type of ECT Stimuli: Burst Stimulus ECT. Pharmacopsychiatry, 2015, 48, 294-296.	1.7	2
41	Markers of the innate immune system in the cerebrospinal fluid in patients with severe depression. Acta Psychiatrica Scandinavica, 2017, 136, 140-141.	2.2	2
42	Electroconvulsive Therapy in a Patient After Radiation Treatment of a Brain Metastasis. Journal of ECT, 2012, 28, 250-251.	0.3	1